Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma.

ABSTRACT:

Introduction

Tavokinogene Telseplasmid Electroporation Therapy (TAVO) and Pembrolizumab therapy is being studied in subjects with immune checkpoint inhibitor (ICI) resistant melanoma. TAVO is a novel office-based local therapy shown to be effective in patients with advanced melanoma. The technique involves the direct injection of a plasmid encoding IL-12 into an accessible tumor driven by electroporation. The tumor cells have then been shown to express high levels of IL-12 resulting in a local inflammatory response within the tumor microenvironment.

Presentation of case

The patient with stage IIB, pT3b melanoma was treated with primary tumor resection and found to have a negative sentinel node biopsy. She subsequently developed regional recurrence and was treated with inguin

SUBMITTER: Dollin Y 

PROVIDER: S-EPMC7708754 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature